[go: up one dir, main page]

PE20050986A1 - Derivados heterociclicos mediadores del transporte inverso de colesterol - Google Patents

Derivados heterociclicos mediadores del transporte inverso de colesterol

Info

Publication number
PE20050986A1
PE20050986A1 PE2005000658A PE2005000658A PE20050986A1 PE 20050986 A1 PE20050986 A1 PE 20050986A1 PE 2005000658 A PE2005000658 A PE 2005000658A PE 2005000658 A PE2005000658 A PE 2005000658A PE 20050986 A1 PE20050986 A1 PE 20050986A1
Authority
PE
Peru
Prior art keywords
cholesterol
reverse transport
same
mediators
cyclic derivatives
Prior art date
Application number
PE2005000658A
Other languages
English (en)
Inventor
Igor Nikoulin
Richard J Thomas
Haripada Khatuya
Jagadish C Sircar
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34981590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050986(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of PE20050986A1 publication Critical patent/PE20050986A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

REFERIDA A UN MEDIADOR DEL TRANSPORTE INVERSO DE COLESTEROL, QUE COMPRENDE (A) UN AMINOACIDO CONTENIENDO UN GRUPO ACIDO O UN BIOISOSTERO DEL MISMO; (B) UN GRUPO AROMATICO O LIPOFILICO CONTENIENDO UN INHIBIDOR DE LA HMG CoA REDUCTASA O UN ANALOGO DEL MISMO; Y (C) UN AMINOACIDO O ANALOGO DEL MISMO CONTENIENDO UN GRUPO BASICO O UN BIOISOSTERO DEL MISMO. DICHA COMPOSICION MEJORA EL TRANSPORTE INVERSO DE COLESTEROL EN MAMIFEROS Y ES UTIL EN LA PREVENCION Y TRATAMIENTO DE HIPERCOLESTEROLEMIA, ATEROSCLEROSIS, ENTRE OTRAS
PE2005000658A 2004-06-09 2005-06-09 Derivados heterociclicos mediadores del transporte inverso de colesterol PE20050986A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57822704P 2004-06-09 2004-06-09

Publications (1)

Publication Number Publication Date
PE20050986A1 true PE20050986A1 (es) 2006-02-03

Family

ID=34981590

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000658A PE20050986A1 (es) 2004-06-09 2005-06-09 Derivados heterociclicos mediadores del transporte inverso de colesterol

Country Status (18)

Country Link
US (1) US20060009487A1 (es)
EP (1) EP1753724A1 (es)
JP (1) JP2008502736A (es)
KR (1) KR20070026598A (es)
CN (1) CN1968928A (es)
AR (1) AR049216A1 (es)
AU (1) AU2005255011A1 (es)
BR (1) BRPI0511822A (es)
CA (1) CA2568394A1 (es)
IL (1) IL179210A0 (es)
MX (1) MXJL06000069A (es)
NO (1) NO20070139L (es)
PE (1) PE20050986A1 (es)
RU (1) RU2006145961A (es)
TW (1) TW200602042A (es)
UY (1) UY28953A1 (es)
WO (1) WO2005123686A1 (es)
ZA (1) ZA200700156B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026480B2 (en) * 2001-03-08 2006-04-11 The University Of Hong Kong Organometallic light-emitting material
US20070004644A1 (en) * 2004-06-09 2007-01-04 Sircar Jagadish C Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
EP1847531A4 (en) * 2005-02-09 2009-04-22 Takeda Pharmaceutical PYRAZOLE DERIVATIVE
GB0619611D0 (en) 2006-10-04 2006-11-15 Ark Therapeutics Ltd Compounds and their use
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
US8592592B2 (en) 2010-04-02 2013-11-26 Senomyx, Inc. Sweet flavor modifier
AU2012295255B2 (en) 2011-08-12 2016-04-21 Senomyx, Inc. Sweet flavor modifier
CN103497151B (zh) * 2013-10-30 2015-07-15 山东铂源药业有限公司 一种4-氨基-6-甲基烟酸的合成方法
CA2963901A1 (en) 2014-11-07 2016-05-12 Senomyx, Inc. Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers
CN106187887B (zh) * 2016-07-01 2018-08-14 上海工程技术大学 4-羟基喹啉-3-甲酸的制备方法
CN109790170B (zh) 2016-08-16 2022-08-02 Uwm研究基金会有限公司 Gaba(a)受体调节剂和控制哮喘中气道高反应性和炎症的方法
CN108623561B (zh) * 2017-03-24 2025-04-01 中国海洋大学 一种制备哌尼诺酸化合物的方法
CN108456154A (zh) * 2018-04-13 2018-08-28 昆明理工大学 一种n-叔丁氧羰基烃基胍的制备方法
EP3911640A4 (en) * 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
MA54261B1 (fr) * 2019-01-18 2025-03-28 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procédés d'utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US3773946A (en) * 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) * 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) * 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
JPH10316641A (ja) * 1997-03-14 1998-12-02 Sankyo Co Ltd カルボン酸誘導体
AU8334298A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
IL145712A0 (en) * 1999-04-01 2002-07-25 Esperion Therapeutics Inc Ether compounds, compositions, and uses thereof
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
FR2820435B1 (fr) * 2001-02-05 2004-02-27 Genfit S A Procedes d'identification de composes modulant le transport inverse du cholesterol
EP1419770A4 (en) * 2001-08-24 2005-08-03 Shionogi & Co AGENT ACC L RATION OF THE EXPRESSION OF APO AI
US7429593B2 (en) * 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
AU2004233333A1 (en) * 2003-04-22 2004-11-04 Avanir Pharmacueticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia

Also Published As

Publication number Publication date
EP1753724A1 (en) 2007-02-21
NO20070139L (no) 2007-03-08
TW200602042A (en) 2006-01-16
JP2008502736A (ja) 2008-01-31
IL179210A0 (en) 2007-03-08
WO2005123686A1 (en) 2005-12-29
BRPI0511822A (pt) 2007-12-26
KR20070026598A (ko) 2007-03-08
MXJL06000069A (es) 2007-04-10
UY28953A1 (es) 2006-01-31
AU2005255011A1 (en) 2005-12-29
AR049216A1 (es) 2006-07-05
RU2006145961A (ru) 2008-07-20
CA2568394A1 (en) 2005-12-29
ZA200700156B (en) 2008-05-28
US20060009487A1 (en) 2006-01-12
CN1968928A (zh) 2007-05-23

Similar Documents

Publication Publication Date Title
PE20050986A1 (es) Derivados heterociclicos mediadores del transporte inverso de colesterol
ATE540950T1 (de) Aminocyclohexane als dipeptidylpeptidase-iv- hemmer zur behandlung bzw. prävention von diabetes
ATE549926T1 (de) Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
ATE370141T1 (de) Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
EA200700965A1 (ru) Трегалоза и/или изомальтулоза в качестве носителя для сухой ароматической композиции
DE60316416D1 (de) Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
DE602005022320D1 (de) Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
EA200601388A1 (ru) Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
DK1556362T3 (da) Heterocykliske beta-aminodipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
DE602004023932D1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
CL2009000967A1 (es) Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente.
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
IS7391A (is) ACC hindrar
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
ATE417832T1 (de) Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
ECSP045307A (es) Combinacion de compuestos organicos
EA201001404A1 (ru) Амиды 5-оксо-2,3,4,5-тетрагидробензо[b]оксепин-4-карбоновой кислоты и амиды 2,3-дигидробензо[b]оксепин-4-карбоновой кислоты для лечения и предотвращения диабета 1 и 2 типа
BRPI0600194A (pt) composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
PE103799A1 (es) Procedimiento de purificacion de mesilato de alatrofloxacino
BR0009389A (pt) Benzoilpirazóis substituìdos como herbicidas
ATE553077T1 (de) Peptidaseinhibitoren
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DE602006017724D1 (de) Salicylsäurederivate

Legal Events

Date Code Title Description
FC Refusal